Home > Insider Trading > Filing (0001781002-20-000005)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1082038	Durect Corp	DRRX	Pharmaceutical Preparations (2834)	943297098

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1781002	Bleichroeder Lp	1345 Avenue Of The Americas 47Th Floor New York NY 10105		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-02-04	77,500	$1.70	26,554,046	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-02-05	74,998	$1.69	26,629,044	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-02-06	75,000	$1.65	26,704,044	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Footnotes

The reported price in Column 4 is a weighted average price. These shares were bought in multiple transactions. On 02/04/2020, prices ranged from $1.68 to $1.71 per share, inclusive. On 02/05/2020, prices ranged from $1.675 to $1.70 per share, inclusive. On 02/06/2020, prices ranged from $1.605 to $1.69 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares of Common Stock reported herein are indirectly beneficially owned by Bleichroeder, LP (Bleichroeder), a Delaware limited partnership, an investment adviser registered under the Investment Advisers Act of 1940. Bleichroeder is the registered investment adviser to Biotechnology Master Fund, Ltd. as well as to 21 April Fund, LP and 21 April Fund, Ltd. (collectively, the "Funds"). The shares of Common Stock reported herein are directly held by the Funds and other managedaccounts. Bleichroeder disclaims beneficial ownership of the shares of Common Stock held directly by the Funds and other managed accounts except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that Bleichroeder is the beneficial owner of any such securities.